Scancell Holdings PLC (LON:SCLP) target price held steady at 68.00GBX, reported today by Panmure Gordon
- Updated: September 16, 2016
Only yesterday Scancell Holdings PLC (LON:SCLP) traded 4.12% lower at 16.50GBX. The company’s 50-day moving average is 18.35GBX and its two hundred day average is 17.56GBX. The last close is down 7.16% from the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Volume of trade was was up over the average, with 672,046 shares of SCLP changing hands over the typical 166,883 shares..
Scancell Holdings PLC (LON:SCLP) had its estimated target price hold steady to 68GBX by Panmure Gordon in a report issued 9/16/2016. The updated target price implies a possible upside of 3.12% based on the company’s previous stock close price.
On 7/20/2016, Panmure Gordon reported about Scancell Holdings PLC(LON:SCLP) maintained the target price at 68.00GBX. At the time, this suggested an upside of 2.53%.
Recent Performance Chart:
In addition to Panmure Gordon reporting it’s stock price target, a total of 1 brokerage has issued a report on the stock. The one year target is 68.00GBX with 0 rating the stock a strong buy, one analyst rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and finally 0 analysts rating the stock as sell.
Scancell Holdings PLC has a one-year low of 12.00GBX and a 52 week high of 29.06GBX. The company’s market capitalization is currently 0.0 GBX.
General Company Details For Scancell Holdings PLC (LON:SCLP)
Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects. Its ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system, where inflammation is stimulated at the tumor site and the cytotoxic T-lymphocyte response, where immune system cells are primed to recognize and kill specific cells. The Moditope immunotherapy platform is based on exploiting the normal immune response to stressed cells, mediated by cluster of differentiation 4+ T cells, and and harnessing this mechanism to eradicate cancer cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.